Directorate Change

Synexus Clinical Research PLC 18 September 2006 Synexus Clinical Research plc appoints Paul McCluskey as Chief Financial Officer Synexus Clinical Research plc ("Synexus") the international organisation providing patient recruitment to the global clinical trials industry, is pleased to announce the appointment of Paul McCluskey as Chief Financial Officer with immediate effect. Most recently, Paul, aged 42, was the European Managing Director of the formerly autonomous subsidiary of RHM plc, RHM Ingredients Ltd, which was acquired by private American owners. He is a fellow of the Institute of Chartered Accountants and previously held finance positions with BAE Systems plc and GlaxoSmithKline plc. Paul succeeds Chris Neilson, the previous Finance Director of Synexus, who is leaving the company to pursue other opportunities. The board would like to thank Chris and wish him well for the future. Michael Fort, CEO of Synexus, commented "We are delighted to have attracted Paul to Synexus. He has considerable experience of managing acquisitions and integrating those operations into a unified business. Synexus' strategy is to build, through targeted acquisitions, an international patient recruitment capability to manage large numbers of clinical trial patients for pharmaceutical clients. Paul's experience in integrating businesses, systems and management teams will strengthen our overall capabilities as we continue to expand." The following information is given in respect of Paul McCluskey as required by Schedule 2 paragraph (g) of the AIM Rules. Directorships held within the previous five years Newly Weds Foods (Europe) Limited Newly Weds Foods Limited NWF Europe Limited RHM Ingredients Limted Press enquiries: Synexus Clinical Research plc Tel: +44 (0)1257 230 723 Michael Fort, Chief Executive Biddicks - Financial Public Relations Tel: +44 (0)20 7448 1000 Zoe Biddick This information is provided by RNS The company news service from the London Stock Exchange

Companies

Synectics (SNX)
UK 100